Foreign Currency Exchange Concept Illustration. United States Dollars Price Rise. Stock Exchange.
WISCONSIN (CoinChapter.com): Today’s top stock soared with a 93% gain, while earlier in the trading day peaked at over 150%. Aurora Acquisition Corp. (NASDAQ: AURC), announced the resumption of trading for its esteemed Class A Ordinary Shares.
Why These Companies Rallied:
Aurora Acquisition Corp. (NASDAQ: AURC)
Aurora Acquisition Corp. announced the resumption of trading for its esteemed Class A Ordinary Shares today. This significant move marks a noteworthy milestone for the corporation and its shareholders. The news is particularly welcomed by investors and market enthusiasts keenly awaiting Trading Class A’s resumption.
Additionally, Virtu Financial LLC disclosed its new position in Aurora Acquisition through a filing with the Securities and Exchange Commission. The firm acquired 17,821 shares of Aurora Acquisition, valued roughly at $180,000.
This investment represents about 0.20% of Aurora Acquisition’s total shares. Other institutional investors, including Cubist Systematic Strategies LLC, have also recently adjusted their stakes in the company.
AURC daily chart. Credit: Stocktwits
INVO BioScience Inc. (NASDAQ: INVO)
INVO Bioscience, Inc. made a significant announcement today, stating that it will implement a 1-for-20 reverse split of its authorized, issued, and outstanding common stock.
This change will occur at 12:01 a.m. Eastern Time on July 28, 2023. Post the reverse stock split, every 20 shares of issued and outstanding common stock will be consolidated into one share, and the new CUSIP number for the Company’s common stock will be 44984F401.
Immediately after the reverse stock split becomes effective, the company will have approximately 842,017 shares of common stock issued and outstanding.
INVO daily chart. Credit: Stocktwits
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
Biogen Inc. will acquire Reata Pharmaceuticals at approximately $7.3 billion — at a rate of $172.50 per share in cash. The move comes as Reata has made substantial progress in developing therapeutics that regulate cellular metabolism and inflammation in serious neurologic diseases.
Reata’s FDA-approved SKYCLARYS® (omaveloxolone) is the pioneering and sole approved treatment for Friedreich’s ataxia in the United States.
RETA daily chart. Credit: Stocktwits
Bluejay Diagnostics, Inc. (NASDAQ: BJDX)
Bluejay Diagnostics, Inc., a leading medical technology company recognized for its Symphony platform, announced a 1-for-20 reverse stock split four days ago.
The move significantly reduced the number of authorized outstanding shares of common stock from 100,000,000 to 7,500,000. The reason for a four-day gap until the stock price popped is unknown as there is no other fresh news, but Bluejay’s commitment to enhance shareholder value while continuing its mission to improve patient outcomes is a positive for investors.
BJDX daily chart. Credit: Stocktwits
View, Inc. (NASDAQ: VIEW)
On July 26, 2023, View, Inc. completed a significant corporate move by filing a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation with the State of Delaware. This was done to execute a 60-for-1 reverse stock split of the outstanding shares of the Company’s Class A common stock.
View works to enhance human health and experiences, reducing energy consumption and carbon emissions and ultimately creating additional revenue streams for building owners.
VIEW daily chart. Credit: Stocktwits
